{
Matthew Weston

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV

ubs maintains neutral rating for roche with target price of 270 francs

UBS has maintained a "Neutral" rating for Roche, setting a price target of 270 Swiss francs following insights from pharmaceuticals chief Teresa Graham at an investor conference. Analyst Matthew Weston noted Roche's confidence in achieving sustainable, currency-adjusted growth of 9 percent.
MarketScreener
Swiss Franc Roche Holding AG CHE Teresa Graham Matthew Weston Show more
TradFi, Market Report
14:51 13.11.2024

ubs maintains sell rating on astrazeneca with target price of 11300 pence

UBS has maintained a 'Sell' rating on AstraZeneca, setting a target price of 11,300 pence, following insights from a Q&A with the company's China finance chief, Aradhana Sarin. Analyst Matthew Weston noted the positive initiative to engage with the financial market amid an ongoing investigation involving Executive Vice President Leon Wang, although AstraZeneca could not provide a timeline for the investigation's conclusion or potential penalties.
aktiencheck.de
British Pound Sterling AstraZeneca PLC GBR Leon Wang Matthew Weston Aradhana Sarin Show more
TradFi, Market Report
10:34 07.11.2024

ubs maintains sell rating for astrazeneca with target price of 11300 pence

UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence ahead of the company's quarterly results. Analyst Matthew Weston noted that his forecasts align closely with consensus estimates.
MarketScreener
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
TradFi, Market Report
17:34 05.11.2024

ubs maintains sell rating for astrazeneca with target price of 11300 pence

UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence ahead of the company's quarterly results. Analyst Matthew Weston noted that the forecasts align closely with consensus estimates.
boerse.de
British Pound Sterling AstraZeneca PLC CHE GBR Matthew Weston Hubert Dichtl Thomas Müller Show more
TradFi, Market Report
16:47 05.11.2024

ubs maintains sell rating on astrazeneca with target price of 11300 pence

UBS has maintained a 'Sell' rating for Astrazeneca, setting a target price of 11,300 pence. Analyst Matthew Weston cautioned that preliminary data on weight loss from the oral drug GLP-1 AZD5004 should not lead to definitive conclusions regarding its effectiveness in overweight patients.
MarketScreener
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
TradFi, Market Report
21:58 04.11.2024

ubs maintains sell rating for astrazeneca with target price of 11300 pence

UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence. Analyst Matthew Weston cautioned that preliminary data on the oral GLP-1 AZD5004 for weight loss should not lead to definitive conclusions regarding its effectiveness in overweight patients.
aktiencheck.de
British Pound Sterling Euro AstraZeneca PLC DEU GBR Matthew Weston
TradFi, Market Report
21:11 04.11.2024

ubs maintains neutral rating for roche shares with price target of 270 francs

UBS AG has maintained a "Neutral" rating for Roche shares, setting a price target of 270 francs. Despite a recent 1.3% decline to CHF 272.80, the stock has seen a 16.2% increase over 2024, with upcoming Q4 2024 financial results expected on January 30, 2025.
finanzen.ch
Swiss Franc Hoffmann-La Roche AG CHE Matthew Weston
TradFi, Market Report
13:43 30.10.2024

ubs maintains neutral rating on roche with target price of 270 francs

UBS has maintained a 'Neutral' rating for Roche, setting a price target of 270 francs. Analyst Matthew Weston noted that recent interim results highlight the superior safety profile of the Alzheimer's antibody trontinemab. The last closing price was 276.30 CHF, with an average target price of 303.76 CHF, indicating a potential upside of 9.94%.
MarketScreener
Swiss Franc Roche Holding AG CHE Matthew Weston Show more
TradFi, Market Report
12:54 30.10.2024

ubs maintains neutral rating for roche with target price of 270 francs

UBS has maintained a 'Neutral' rating for Roche, setting a price target of 270 francs. Analyst Matthew Weston noted that recent interim results highlight the superior safety profile of the Alzheimer's antibody trontinemab. The original study is set to be published on October 30, 2024.
aktiencheck.de
Swiss Franc Hoffmann-La Roche AG CHE Matthew Weston
TradFi, Market Report
12:54 30.10.2024

ubs maintains neutral rating for roche with target price of 270 francs

UBS has maintained a "Neutral" rating for Roche, setting a target price of 270 Swiss francs. Analyst Matthew Weston noted that recent interim results highlight the superior safety profile of the Alzheimer's antibody trontinemab.
boerse.de
Swiss Franc Hoffmann-La Roche AG CHE Matthew Weston
TradFi, Market Report
12:54 30.10.2024
Trending
Subcategory
Corporate News Industry Trends Stock Market Updates Retail and Consumer Goods Global Financial Events Finance Mergers & Acquisitions Global Trade Developments Central Bank Actions Industry Mergers & Acquisitions Banking Regulations CEO Changes Startups & Entrepreneurship Market Analysis and Predictions Financial Scams and Security Supply Chain Management Workplace Trends Government Economic Policies AI Innovations Energy Sector Developments Cryptocurrency Trends
Countries:
USA CHN GBR IND CHE CAN JPN FRA DEU MEX RUS SGP BRA ZAF AUT ARE SAU ITA IDN IRL
Companies:
The Goldman Sachs Group, Inc. Bank of America Corporation Apple Inc. Barclays PLC Wells Fargo & Company Alphabet Inc. Tesla, Inc. Citigroup Inc. Lloyds Banking Group plc Deutsche Bank RV Global PP PepsiCo, Inc. Commerzbank AG Google Inc. NatWest Group plc BNP Paribas SA Morgan Stanley UBS Group AG JPMorgan Chase & Co. NVIDIA Corporation Amazon.com, Inc.
Currencies:
United States Dollar Euro Chinese Yuan British Pound Sterling Swiss Franc Indian Rupee Japanese Yen Indonesian Rupiah Canadian Dollar Russian Ruble South Korean Won United Arab Emirates Dirham Offshore Chinese Yuan Ghanaian Cedi Hungarian Forint Albanian Lek Brazilian Real Singapore Dollar Qatari Riyal Jordanian Dinar
People:
Donald Trump Elon Musk Warren Buffett Goldman Sachs Sergey Brin Larry Page Kelvin Taylor Scott Bessent Joe Biden Carsten Fritsch Rachel Reeves Brian Moynihan Christopher Chandler Martin Schlegel Jerome Powell Kubra Khan Volkmar Baur Christopher Wallerstedt Jamie Dimon Karoline Leavitt

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.